Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Dive

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Lipid Mediators and Cell Signalling|January 1, 1997
Design and modeling of new platelet-activating factor antagonists. 2. Synthesis and biological activity of 1,4-bis-(3',4',5'-trimethoxybenzoyl)-2-alkyl and 2-alkyloxymethylpiperazinesF Tavet, A Lamouri, F Heymans, et al.
The Biochemical Journal|September 15, 1991
The importance of the negative charge of beta-lactam compounds in the interactions with active-site serine DD-peptidases and beta-lactamasesL Varetto, F De Meester, D Monnaie, et al.
Journal of Lipid Mediators|July 1, 1989
PAF-receptor. 1. 'Cache-oreilles' effect of selected high-potency platelet-activating factor (PAF) antagonistsG Dive, J J Godfroid, J Lamotte-Brasseur, et al.
Journal of Lipid Mediators and Cell Signalling|May 1, 1996
Structure-activity relationships in platelet-activating factor (PAF). 7. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors. Synthesis and PAF-antagonistic activityL Le Texier, E Favre, C Redeuilh, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2001
Imidazolopyrazinones as potential antioxidantsI Devillers, G Dive, C De Tollenaere, et al.
The Biochemical Journal|May 1, 1984
Active-site-directed inactivators of the Zn2+-containing D-alanyl-D-alanine-cleaving carboxypeptidase of Streptomyces albus GP Charlier, O Dideberg, J C Jamoulle, et al.
Journal of Medicinal Chemistry|April 16, 1993
Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazinesA Lamouri, F Heymans, F Tavet, et al.
Journal of Lipid Mediators and Cell Signalling|January 1, 1997
Design and modeling of new platelet-activating factor antagonists. 3. Relative importance of hydrophobicity and electronic distribution in piperazinic seriesF Heymans, G Dive, A Lamouri, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 7, 2006
Study of the physicochemical properties in aqueous medium and molecular modeling of tagitinin C/cyclodextrin complexesE Ziémons, G Dive, B Debrus, et al.
Lipids|December 1, 1991
PAF receptor and "Cache-oreilles" effect. Simple PAF antagonistsJ Lamotte-Brasseur, F Heymans, G Dive, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Lipid Mediators and Cell Signalling|January 1, 1997
Design and modeling of new platelet-activating factor antagonists. 2. Synthesis and biological activity of 1,4-bis-(3',4',5'-trimethoxybenzoyl)-2-alkyl and 2-alkyloxymethylpiperazinesF Tavet, A Lamouri, F Heymans, et al.
The Biochemical Journal|September 15, 1991
The importance of the negative charge of beta-lactam compounds in the interactions with active-site serine DD-peptidases and beta-lactamasesL Varetto, F De Meester, D Monnaie, et al.
Journal of Lipid Mediators|July 1, 1989
PAF-receptor. 1. 'Cache-oreilles' effect of selected high-potency platelet-activating factor (PAF) antagonistsG Dive, J J Godfroid, J Lamotte-Brasseur, et al.
Journal of Lipid Mediators and Cell Signalling|May 1, 1996
Structure-activity relationships in platelet-activating factor (PAF). 7. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors. Synthesis and PAF-antagonistic activityL Le Texier, E Favre, C Redeuilh, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2001
Imidazolopyrazinones as potential antioxidantsI Devillers, G Dive, C De Tollenaere, et al.
The Biochemical Journal|May 1, 1984
Active-site-directed inactivators of the Zn2+-containing D-alanyl-D-alanine-cleaving carboxypeptidase of Streptomyces albus GP Charlier, O Dideberg, J C Jamoulle, et al.
Journal of Medicinal Chemistry|April 16, 1993
Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazinesA Lamouri, F Heymans, F Tavet, et al.
Journal of Lipid Mediators and Cell Signalling|January 1, 1997
Design and modeling of new platelet-activating factor antagonists. 3. Relative importance of hydrophobicity and electronic distribution in piperazinic seriesF Heymans, G Dive, A Lamouri, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 7, 2006
Study of the physicochemical properties in aqueous medium and molecular modeling of tagitinin C/cyclodextrin complexesE Ziémons, G Dive, B Debrus, et al.
Lipids|December 1, 1991
PAF receptor and "Cache-oreilles" effect. Simple PAF antagonistsJ Lamotte-Brasseur, F Heymans, G Dive, et al.
Pageof 4